Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma
Multiple myeloma is a malignancy of plasma cells of the bone marrow. Although the prognosis is variable, no curative therapy has been defined. Vaccinia virus infects cancer cells and kills such cells in a variety of ways. These include direct infection, triggering of immunomediated cell death, and v...
Main Authors: | Muneyoshi Futami, Kota Sato, Kanji Miyazaki, Kenshi Suzuki, Takafumi Nakamura, Arinobu Tojo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770517300281 |
Similar Items
-
Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
by: Mengyuan Li, et al.
Published: (2023-09-01) -
Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy
by: Xinjun Liu, et al.
Published: (2022-09-01) -
Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
by: Dobrin D. Draganov, et al.
Published: (2019-03-01) -
Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
by: Valentina Marchica, et al.
Published: (2021-02-01) -
Oncolytic vaccinia virus and cancer immunotherapy
by: Lihua Xu, et al.
Published: (2024-01-01)